Tim Boreham

Minnow Inhalerx hopes to be first to market with inhaled synthetic medical cannabis therapies for cancer pain and panic disorders.

Ahead of EBR's official October 1 Us launch of its Wise device, surgeons have already used the heart tool in 12 procedures.

Botanix reports increased US sales of its topical treatment for excessive underarm sweating – although middlemen are taking too much margin.

Fragrant candle maker Dusk Group is expanding into the personal care category, to capture a younger customer base - and more males.

The local biotech sector is in recovery mode today, having fallen sharply on Friday after Trump's announcement of a 100% pharma tariff.

With extensive upcoming drug launches, NZ's Aft Pharmaceuticals is confident of hitting its $270 million revenue target by March 2027.

Starpharma has struck a headline $855m deal with Big Pharma Genentech to develop drugs that include the company's dendremer based candidates.

Emvision Medical Devices (ASX:EMV) hopes its Emu and First Responder devices will enable detection in the crucial first hour.

Imagion shares are on a tear after the US FDA said it had no objections to the proposed conduct of a phase II breast cancer imaging trial. 

Listed IT consultancy Atturra says AI means burgeoning data needs - and that means a growing risk of data breaches and other threats.